Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT ID: NCT00075543
Last Updated: 2008-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
INTERVENTIONAL
2003-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel and oxaliplatin and to see how well they work in treating patients with stage III or stage IV ovarian epithelial cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine the maximum tolerated dose of docetaxel and oxaliplatin in patients with stage III or IV ovarian epithelial cancer.
* Determine the toxicity of this regimen in these patients.
Secondary
* Determine the tolerance profile of patients treated with this regimen.
* Determine a recommended phase III dose of this regimen in these patients.
* Determine the efficacy of this regimen, in terms of objective response rate and radiological and biological response rate (CA 125), in these patients.
* Determine the complete pathological response in patients treated with this regimen as first-line therapy.
* Determine the duration of the objective response in patients treated with this regimen.
* Determine the time to progression in patients treated with this regimen.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed monthly for 3 months.
PROJECTED ACCRUAL: A total of 30-39 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
docetaxel
oxaliplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed ovarian epithelial cancer
* Stage III or IV disease
* Metastatic peritoneal, lymphatic, or visceral disease
* Measurable or evaluable disease
* Previously untreated disease OR relapsed disease more than 6 months after the completion of a platinum-containing chemotherapy regimen
* No symptomatic brain metastases
PATIENT CHARACTERISTICS:
Age
* 18 to 75
Performance status
* WHO 0-2 (0 in patients 70 to 75 years of age)
Life expectancy
* Not specified
Hematopoietic
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic
* Bilirubin no greater than 1.25 times upper limit of normal (ULN)
* AST and ALT no greater than 3 times ULN
* Alkaline phosphatase less than 2.5 times ULN
Renal
* Creatinine no greater than 1.4 mg/dL
Other
* No serious uncontrolled infection
* No intolerance to polysorbate 80
* No peripheral neuropathy greater than grade 1
* No neurological or mental disease that would preclude study participation
* No other prior malignancy except curatively treated basal cell skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* See Disease Characteristics
* More than 4 weeks since prior chemotherapy
* No more than 1 prior chemotherapy regimen
* No prior oxaliplatin or docetaxel
Endocrine therapy
* Not specified
Radiotherapy
* More than 4 weeks since prior radiotherapy
Surgery
* Not specified
Other
* More than 28 days since prior participation in another clinical study
* No other concurrent anticancer treatment
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GERCOR - Multidisciplinary Oncology Cooperative Group
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christophe Tournigand
Role: STUDY_CHAIR
Hopital Saint Antoine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intercommunal Hospital
Montfermeil, , France
Hopital Saint Antoine
Paris, , France
Hopital Tenon
Paris, , France
Polyclinique De Courlancy
Reims, , France
C.H. Senlis
Senlis, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FRE-GERCOR-DOCELOX/O-01-1
Identifier Type: -
Identifier Source: secondary_id
EU-20332
Identifier Type: -
Identifier Source: secondary_id
CDR0000346887
Identifier Type: -
Identifier Source: org_study_id